Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
McGill University · McGill University Health Centre
Abstract
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its increasing integration into clinical practice. Carrying tumor specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a focus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.
Citation impact
- FWCI
- 123.68
- Percentile
- 100%
- References
- 304
Authors
8- ABAlexandra Bartolomucci
McGill University, McGill University Health Centre
- MDMonyse de Nóbrega
McGill University Health Centre, McGill University
- TFTadhg Ferrier
McGill University Health Centre, McGill University
- KDKyle Dickinson
McGill University Health Centre
- NKNivedita Kaorey
McGill University, McGill University Health Centre
Topics & keywords
- Precision oncology
- Solid tumor
- Circulating tumor DNA
- Oncology
- Clinical Oncology
- Internal medicine
- DNA
- Cancer research
- Good health and well-being